Emtricitabine Capsules
Dosage form: capsule
Drug class:Nucleoside reverse transcriptase inhibitors (NRTIs)
Medically reviewed by Drugs.com. Last updated on Apr 1, 2022.
On This Page
- Boxed Warning
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued emtricitabine.Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue emtricitabine. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1)].
Indications and Usage for Emtricitabine Capsules
Emtricitabine is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Emtricitabine Capsules Dosage and Administration
2.1 Testing Prior to Initiation of Treatment with Emtricitabine
Prior to or when initiating emtricitabine, test patients for hepatitis B virus infection [seeWarnings and Precautions (5.1)].
Recommended Dosage
Emtricitabine is taken by mouth once daily and may be taken without regard to food [see Clinical Pharmacology (12.3)].
Recommended Dosage in Adult Patients (18 years of age and older)
Emtricitabine Capsules: One 200 mg capsule administered once daily orally.
